RT Journal Article
SR Electronic
T1 Pre-clinical Study of BK-UM, a Novel Inhibitor of HB-EGF, for Ovarian Cancer Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4615
OP 4620
VO 34
IS 8
A1 SUNG OUK NAM
A1 FUSANORI YOTSUMOTO
A1 KOHEI MIYATA
A1 YUKI SUZAKI
A1 HIROSHI YAGI
A1 TAKASHI ODAWARA
A1 SADAO MANABE
A1 TOYOKAZU ISHIKAWA
A1 MASAHIDE KUROKI
A1 EISUKE MEKADA
A1 SHINGO MIYAMOTO
YR 2014
UL http://ar.iiarjournals.org/content/34/8/4615.abstract
AB Background/Aim: Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the epidermal growth factor family, is a target for ovarian cancer therapy. The present study investigated the administration schedule of BK-UM, an anticancer agent targeting HB-EGF. Materials and Methods: The ovarian cancer cell line, RMG-I, was injected subcutaneously into five-week-old female nude mice. The BK-UM was administered intraperitoneally, using three administration schedules with different doses. The tumor volume was calculated every week. Statistical significance was assessed using the Mann–Whitney U-test. Results: At doses >0.1 mg/kg, BK-UM displayed significant antitumor effects, although the antitumor effects and body weights of mice did not significantly differ by dose or by three different administration schedules. At a dose <0.1 mg/kg, however, BK-UM had little inhibitory effect on tumor growth. Conclusion: Daily administration of BK-UM, which has a potentially dose-dependent antitumor effect, may be the optimal schedule for clinical application.